Bank of America Corp DE cut its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 12.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,240,440 shares of the medical equipment provider's stock after selling 176,622 shares during the quarter. Bank of America Corp DE owned approximately 0.29% of Smith & Nephew SNATS worth $39,421,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of SNN. River Road Asset Management LLC boosted its holdings in shares of Smith & Nephew SNATS by 13.8% during the 4th quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider's stock worth $103,996,000 after purchasing an additional 384,926 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Smith & Nephew SNATS by 5.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider's stock worth $67,383,000 after buying an additional 100,697 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Smith & Nephew SNATS by 44.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,052,747 shares of the medical equipment provider's stock valued at $33,436,000 after buying an additional 324,080 shares in the last quarter. Todd Asset Management LLC increased its stake in shares of Smith & Nephew SNATS by 30.2% in the 4th quarter. Todd Asset Management LLC now owns 944,578 shares of the medical equipment provider's stock worth $30,992,000 after acquiring an additional 219,348 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Smith & Nephew SNATS by 45.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 937,943 shares of the medical equipment provider's stock worth $34,038,000 after acquiring an additional 293,418 shares during the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.
Smith & Nephew SNATS Price Performance
Shares of SNN stock opened at $30.14 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14. The firm's 50 day moving average price is $30.47 and its 200-day moving average price is $32.04. Smith & Nephew SNATS, Inc. has a one year low of $28.56 and a one year high of $38.79.
Smith & Nephew SNATS Dividend Announcement
The company also recently announced a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be issued a dividend of $0.312 per share. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.
Analyst Ratings Changes
SNN has been the topic of several recent research reports. Morgan Stanley reissued an "overweight" rating on shares of Smith & Nephew SNATS in a research report on Wednesday, August 5th. The Goldman Sachs Group restated a "buy" rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. Canaccord Genuity Group reduced their target price on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a "hold" rating on the stock in a research note on Monday, May 11th. Wall Street Zen lowered shares of Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 8th. Finally, Kepler Capital Markets cut shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Thursday, June 4th. Two investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $30.93.
Check Out Our Latest Analysis on SNN
Smith & Nephew SNATS Profile
(
Free Report)
Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.
In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.
See Also
Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Smith & Nephew SNATS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.
While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
